Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Cut the bu11cr@p, I own convenience stores and even when they are extremely stable I don't know how much I'm going to take home at the end of the month. You had a great day, congratulations and enjoy, but cut the cr@p.
Once we enter the CBD world, we need to show ourselves as a CBD company to our peer and potential customers, here is a list of the next CBD events, we need to be there!!!
https://www.cannabisbusinesstimes.com/events/
HC, I have a different suggestion, eliminate your worst seller or 2 every year and keep developing new products, you never know when you are going to hit a megahomerun.
Whoever has being reading my posts would know I've being following Fluticare reviews in amazon very closely, why? quite simple, the more reviews, the more sales we had since Amazon doesn't allow just anyone to review but previous customers; my point of comparison was Fluticasone, at the time we had 24 reviews for the 2 pack, 5 for the 1 pack and 4 for the 4pack while they had 49 for the single pack, this was back in May; today they have 68 comparede to 9 for the 4 pack, 89 for the single pack and 86 for the 2 pack, and they continue to be one of the best sellers in the Allergy categorie, we are killing it in Amazon!!!
look for this part:
Want it Thursday, Nov. 1? Order within 15 hrs 27 mins and choose One-Day Shipping at checkout.
Sold by PRIME Distribution and Fulfilled by Amazon. Gift-wrap available.
Guys, take a look at this, Fluticare is no longer sold and executed by INNOVUS in amazon but directly by AMAZON, this is fantastic news, this means they keep our product in stock at their distribution centers and they are even offering 1 day delivery, check it out...
https://www.amazon.com/FlutiCare-metered-Fluticasone-Propionate-allergens/dp/B0771X51Q2/ref=zg_bs_3760991_27?_encoding=UTF8&psc=1&refRID=61KJSQN39WG45EXJS8FG
We know it's not dilution since the total share count only went up 5 million shares, we know it's not insiders since no disclosure has being made, so, my guess is... penny flippers.
Just 4 left!!
Hey guys, everyone remembers Dr Da saying profitability is the main goal for 2018, they are in a under promise over deliver mode this year, he realized they were losing credibility by doing the opposite so, since we are only 2 months away from the end of the year I'm going to start a count down to moneyland starting November 1st. I truly believe they can pull it off since Amazon reviews are growing exponentially and all of them are verified purchases and that's a good indication the products are gaining traction, besides, I wouldn't be surprised if a few distributor start to buy some of our products in bulk at Alibaba to position them in their routes, after all we all know how competitive their prices are compared to branded products. oh, by the way we are only 63 days away from Dec 31st.
https://trademarks.justia.com/875/27/musclin-87527180.html
look at the status of MUSCLIN as of 10/23/2018
Mynah, I know it's halloween time, but no one is scaring this investor.
Good luck my friend, I'll see you at the top!!!
We are now entering the CBD industry so this applies to us.
https://www.prnewswire.com/news-releases/cannabis-companies-ramp-up-diversified-product-development-as-cbd-industry-explodes-beyond-expectations-817477369.html
where is awaitingadoomday?
We got to push the management team to start going to pharma trade shows, we need our products out there where the big buyers can see us!!!
This is a very unexpensive and eficient idea for management to get Musclin to the right hands in no time, contact a group of young fitness influencers with a decent amount of followers(the ones with millions of followers are expensive, the ones with tens of thousands are not) to take a picture with a bottle of INNOVUS Musclin and post it in instagram, facebook and tweeter and we will see it fly off shelves.
Why are you curious? YOU DON'T OWN A SINGLE SHARE!! if you are curious go and watch curious George, you might find it quite interesting, or go and try to solve jack the ripper's case, do something productive with your life and stop wasting people's time with your bull&%*%$##.
More good news keep piling up...
CBD Market Growth Projections Dramatically Higher Than Expected, Generating Strong Revenues
8:45 am ET October 23, 2018 (PR Newswire) Print
Financialnewsmedia.com News Commentary
The Cannabinoid (CBD) sector continues to illustrate strong revenue growth with projections favoring a continued trend of consistency as cannabis-extracts and CBD-based products become synonymous with mainstream markets. The CBD market has just about doubled in size over the past two years and is expected to surpass the billion-dollar mark within the next two years according to forecasts from multiple analysts. CBD continues to experience this unrelenting growth largely due to the fact that it does not have as many hurdles to jump over compared to traditional cannabis, especially as it relates to regulations and logistical issues. Other factors working in CBD's favor include the wide variety of CBD products hitting the market, increased consumer adoption and leaders in the industry steadily investing in research and development to tap into new markets.
Innovus Pharma Receives Approval for Medicare Reimbursement for its GlucoGorx(TM) Blood Glucose Monitoring System and GlucoGorx(TM) Blood Glucose Test Strip Products
6:10 am ET October 23, 2018 (BusinessWire) Print
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company") (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men's and women's health and respiratory diseases, announced today that its GlucoGorx(TM) Blood Glucose Monitoring System and GlucoGorx(TM) Blood Glucose Test Strip products have become eligible for Medicare reimbursement. Specifically, the two products have been approved as Healthcare Common Procedure Coding System ("HCPCS") numbers E0607 and A4253 products respectively after review by the Pricing, Data Analysis, and Coding Contractor ("PDAC") for the U.S. Centers for Medicare and Medicaid Services ("CMS").
"We are delighted with the approval of our products, GlucoGorx(TM) Blood Glucose Monitoring System and GlucoGorx(TM) Blood Glucose Test Strips, to be eligible for reimbursement under Medicare," said Dr. Bassam Damaj, the President and Chief Executive Officer of Innovus Pharma. "The Medicare reimbursement is a great validation of our product by this U.S. federal governmental authority and we believe this will open for us a new sales channel with hospitals and physicians and permit more customers to consider and purchase these products."
The Company will begin working with multiple leading hospitals and other providers on potentially adding these products to their formularies and with certain high physician prescribers to start recommending these products to their patients.
About the GlucoGorx(TM) Glucose Monitor, Lancet and Test Strips
The GlucoGorx(TM) Kits are FDA-cleared tests for the monitoring of blood sugar levels in diabetics. The test has undergone clinical trials and the results can be seen by customers within four seconds.
According to a June 22, 2017Research and Marketspublished report, "Glucose Monitoring Global Market - Forecast to 2023," the Glucose Monitoring global market is forecasted to reach to $11.24 billion by 2023 and grow at single digit CAGR.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists,gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application ("ANDA") products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.
Something to consider!!
INNV should start talking to MEDLINE, it's the biggest distributor of med supplies in the world and they can position the meters and strips in a matter of seconds.
The solution is very very simple, Dr Da or one of the directors spends $50000 buying INNV stocks, the news of an insiders purchase will spread like wild fire, stocks will rise and then they can sell some shares at a decent price. It won't take long before we reach profitability.
Lots of you know me from the beginning of the year when POTN went all the way to .90 cents, you can't tell I didn't say so, I told you many times and I made over a million dollars with it, then I told you it was time to go out when this stock was .40 cents and it went down to the 20's, I came back about 2 months ago and told you it was time to buy again before Canada and even some of you wrote to me asking why I was so sure about that, well history tends to repeat itself and it did a few days ago when POTN grew like 50% over night. I honestly don't see any big moves by POTN in the near future, but I'm following a company that is so undervalued right now is just insane and I believe it will move like POTN did in a matter of months.
Disclosure: this is my opinion, it's based on my analysis and I might be wrong but in my mind there are no doubts.
Use those 1200 dollars as a down payment for an air conditioner to see if your view of the world improves a bit, you are way to negative and it might be the heat...or the cold depending where you live.
Have you guys seen those bums who sit in front of a bank and they keep talking about financial crisis and how the banks rip people off but they don't have an account and the financial crisis nor stability affects them? Well, we have our own bum in this chat... can you guess who???
and why exactly do you care if you don't own a single share; go ahead and buy or F OFF.
Innovus Pharma Announces Planned Expansion into CBD Oil-Based Products Market
6:01 am ET October 18, 2018 (BusinessWire) Print
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company") (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men's and women's health and respiratory diseases, today announced that it plans to expand its product line into the hemp-derived CBD ("Cannabinoid") oil-based products market beginning in the fourth quarter 2018 with the introduction of MZS Sleeping Aid(TM), a supplement in tincture form delivering a 3 mg dose of melatonin per serving that incorporates either 100 or 250 mg of hemp-derived CBD oil. The product is intended to be sold as a supplement in the U.S. and eventually, pending regulatory approval, into the Canadian market. Innovus is also interested in expanding into other products using hemp-derived CBD oil that can benefit its customers in both countries and in other markets throughout the world.
MZS Sleeping Aid(TM) is currently expected to be launched in states in the U.S. where hemp-derived CBD products may be sold. The product to be launched will not contain any THC (Tetrahydrocannabinol) and is designed to be compliant with applicable U.S. state and federal laws.
"We are very excited to be expanding into the hemp-derived CBD oil-based product market with the commercialization of this melatonin product that includes CBD oil intended for persons to improve their sleep," said Dr. Bassam Damaj, the President and Chief Executive Officer of Innovus Pharma. "The successful commercialization of this product will hopefully lead to our development of more products utilizing hemp-derived CBD oil-based ingredients. By developing and commercializing such products, we believe we are expanding our product offerings to provide our customers with a CBD alternative to realizing and achieving their healthcare goals."
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly; (b) commercial partners to primary care physicians, urologists,gynecologists and therapists; and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application ("ANDA") products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.
For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; www.apeaz.com; and www.diabasens.com.
Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues from the sale of its future CBD oil-based products, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
nnovus Pharma Announces Planned Expansion into CBD Oil-Based Products Market
6:01 am ET October 18, 2018 (BusinessWire) Print
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company") (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men's and women's health and respiratory diseases, today announced that it plans to expand its product line into the hemp-derived CBD ("Cannabinoid") oil-based products market beginning in the fourth quarter 2018 with the introduction of MZS Sleeping Aid(TM), a supplement in tincture form delivering a 3 mg dose of melatonin per serving that incorporates either 100 or 250 mg of hemp-derived CBD oil. The product is intended to be sold as a supplement in the U.S. and eventually, pending regulatory approval, into the Canadian market. Innovus is also interested in expanding into other products using hemp-derived CBD oil that can benefit its customers in both countries and in other markets throughout the world.
MZS Sleeping Aid(TM) is currently expected to be launched in states in the U.S. where hemp-derived CBD products may be sold. The product to be launched will not contain any THC (Tetrahydrocannabinol) and is designed to be compliant with applicable U.S. state and federal laws.
"We are very excited to be expanding into the hemp-derived CBD oil-based product market with the commercialization of this melatonin product that includes CBD oil intended for persons to improve their sleep," said Dr. Bassam Damaj, the President and Chief Executive Officer of Innovus Pharma. "The successful commercialization of this product will hopefully lead to our development of more products utilizing hemp-derived CBD oil-based ingredients. By developing and commercializing such products, we believe we are expanding our product offerings to provide our customers with a CBD alternative to realizing and achieving their healthcare goals."
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly; (b) commercial partners to primary care physicians, urologists,gynecologists and therapists; and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application ("ANDA") products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.
For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; www.apeaz.com; and www.diabasens.com.
Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues from the sale of its future CBD oil-based products, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
that's nothing, INNV sold 8.8M last year and as of June they have sold 11.3M, INNV will do +300% YOY at this rate and next year we are going to enter the European and Asian Market.
$INNV-Innovus Pharma-(((NEWS-OUT)))-Expanding-to-ASIA!
Business Wire•October 15, 2018
SAN DIEGO--(BUSINESS WIRE)--
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced the approval from Amazon® for the expansion of its Amazon® stores to Japan. The additional store will increase the Company’s worldwide Amazon® store presence to its first country in Asia and is in addition to the Company’s Amazon® stores in the United States, Canada, Mexico and its new stores opening in the United Kingdom, France, Germany, Spain and Italy which it expects to launch in Q1 2019 or before. Innovus Pharma expects to launch its Japanese store in the first quarter of 2019.
“We are delighted with the approval of our new Amazon® store in Japan,” said Dr. Bassam Damaj, the President and Chief Executive Officer of Innovus Pharma. “This expansion of our Amazon® sales to Asia through Amazon’s FBA shipping is a major step to globalize our direct sales without the need to continuously depend on finding local partners. The Japanese expansion of our Amazon® stores follows the successful launches of our stores in the United States, Canada, Mexico and the upcoming launches of our stores in Europe.”
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our online channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.
For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; www.apeaz.com; and www.diabasens.com.
$INNV-Innovus Pharma-(((NEWS-OUT)))-Expanding-to-ASIA!
Business Wire•October 15, 2018
SAN DIEGO--(BUSINESS WIRE)--
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced the approval from Amazon® for the expansion of its Amazon® stores to Japan. The additional store will increase the Company’s worldwide Amazon® store presence to its first country in Asia and is in addition to the Company’s Amazon® stores in the United States, Canada, Mexico and its new stores opening in the United Kingdom, France, Germany, Spain and Italy which it expects to launch in Q1 2019 or before. Innovus Pharma expects to launch its Japanese store in the first quarter of 2019.
“We are delighted with the approval of our new Amazon® store in Japan,” said Dr. Bassam Damaj, the President and Chief Executive Officer of Innovus Pharma. “This expansion of our Amazon® sales to Asia through Amazon’s FBA shipping is a major step to globalize our direct sales without the need to continuously depend on finding local partners. The Japanese expansion of our Amazon® stores follows the successful launches of our stores in the United States, Canada, Mexico and the upcoming launches of our stores in Europe.”
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our online channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.
For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; www.apeaz.com; and www.diabasens.com.
I have the feeling your username is "NEW" at yahoo message board and no one believes a word "New" says.
Innovus Pharma Receives Approval from Amazon(R) to Expand its Amazon(R) Stores to Japan
6:05 am ET October 15, 2018 (BusinessWire) Print
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company") (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men's and women's health and respiratory diseases, today announced the approval from Amazon(R) for the expansion of its Amazon(R) stores to Japan. The additional store will increase the Company's worldwide Amazon(R) store presence to its first country in Asia and is in addition to the Company's Amazon(R) stores in the United States, Canada, Mexico and its new stores opening in the United Kingdom, France, Germany, Spain and Italy which it expects to launch in Q1 2019 or before. Innovus Pharma expects to launch its Japanese store in the first quarter of 2019.
"We are delighted with the approval of our new Amazon(R) store in Japan," said Dr. Bassam Damaj, the President and Chief Executive Officer of Innovus Pharma. "This expansion of our Amazon(R) sales to Asia through Amazon's FBA shipping is a major step to globalize our direct sales without the need to continuously depend on finding local partners. The Japanese expansion of our Amazon(R) stores follows the successful launches of our stores in the United States, Canada, Mexico and the upcoming launches of our stores in Europe."
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists,gynecologists and therapists, and (c) directly to consumers through our online channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application ("ANDA") products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.
For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; www.apeaz.com; and www.diabasens.com.
Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues from the sale of its products in Japan, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
We all know you are scared about your short position, but you don't need to be so obvious ;)
130 million people, huge population of older people, most of them used to buy online. Money is coming our way.
I think we need to accumulate as much as we can before the company reach profitability, because that's when all the investors will show up and are going to start doing YOUR math, the good part is the number for 3rd quarter or even 4th will be in and they will do the math not at 11.3M but let's say 23M and the multiplier might not be 3 but 12.6 like Zack's report suggested.
No, I live in south Florida and it's going to hit north.
Oh, by the way, my order of 12 flutis is alredy home, tomorrow will be displayed at both of my locations.
Even better, we are going to finish up the year with more than 60% of The Medicines's(MDCO) net sales in 2017, a company worth 2.1 Billion dollars and 700 million in net losses for the same year. is INNV undervalued? THAT'S A FREAKING UNDERSTATEMENT!!!!
A few very likely ways we can become a billion dollar company:
1. Fluticare Anda and we go to every major brick and mortar store in the USA.
2. Androferti success at CVS and we go nationwide with the complete line of products.
3. Merging with a large corporation already establish at big retailers.
4. Cialis OTC at Amazon, Walmart, CVS, BEYOND HUMAN, Showcase, ebay and Wish.
Just to mention a few, and we are worth 11 cents.
We only need 1 of these to happen and we will go to the Big Billion